Trial · NCT00104299
Results by group86
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 86
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease Remission | Rituximab | 63 | Participants | ||
| Disease Remission | Control Group | 52 | Participants | ||
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Death | 2 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Death | 2 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Grade 2 or Higher Leukopenia | 7 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Grade 2 or Higher Leukopenia | 23 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Grade 2 or Higher Thrombocytopenia | 4 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Grade 2 or Higher Thrombocytopenia | 1 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Grade 3 or Higher Infections | 18 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Grade 3 or Higher Infections | 16 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Hemorrhagic Cystitis (Grade 2 or Lower) | 2 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Hemorrhagic Cystitis (Grade 2 or Lower) | 1 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Malignancy | 5 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Malignancy | 2 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Venous Thromboembolic Event | 6 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Venous Thromboembolic Event | 8 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Hospitalization Resulting from the Disease | 16 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Hospitalization Resulting from the Disease | 7 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Rituximab | Cerebrovascular Accident (CVA) | 1 | participants | |
| Rate of Selected Adverse Events Experienced by Participants Receiving Rituximab Versus Those Receiving Conventional Therapy | Control Group | Cerebrovascular Accident (CVA) | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00104299/results